US Stem Cell Inc (OTCMKTS:USRM) Starting to Open Eyes

US Stem Cell Inc (OTCMKTS:USRM) Starting to Open Eyes

SHARE

White Papers are used often by Biotech companies as a tool to secure financing and US Stem Cell Inc (OTCMKTS:USRM) utilized a White Paper Series to open the eyes of investors as to how significant the results were. Normally this prompts those who take the time to read them and creates an “Ah Ha”, moment where the light goes on for the investor.

If you look at the timing of the White Paper released by Kristen Comella in late January you can see how the market reacted to this information. The stock went from triple zero sub penny to near .13 cents, which is a very large move. USRM went on to secure financing and has funding for operations for years to come, it is good to see stocks where this process works with fluidity, more microcap stocks should be looking at employing this White Paper marketing strategy to secure investors.

US Stem Cell Inc (OTCMKTS:USRM) is a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients.“Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease” was published in the January volume of the Journal of Translational Medicine. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damaged discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion.

Ms. Comella’s previous paper, “Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy,” was released in the Journal of Translational Medicine‘s June 2016 edition. Using the same procedure, chronic ischemic cardiomyopathy patients were evaluated after SVF injection and able to walk more than 80 additional meters 3 to 6 months after treatment.

Subscribe below and we’ll keep you on top of what’s happening before $USRM stock makes its next move.

$USRM 10-Day Chart Below:

U.S. Stem Cell, Inc., is committed to new technological advancements and therapies that give a renewed sense of hope to patients with degenerative diseases. SVF is the latest therapy in a long line of successful treatments the company pioneered. Ms. Comella plans to continue her work with SVF, which has consistently repeated its strong safety profile and success in treating patients.

The second piece of the puzzle was raising capital and the company recently secured a commitment to invest up to $5,000,000 from private equity firm General American Capital Partners LLC (GACP) in exchange for up to 63,873,275 shares of common stock.

“We see exponential growth in the stem cell industry, estimated to grow to $170 billion by 2020,” said Joseph DaGrosa, Jr., a Principal with General American Capital Partners. “We are very pleased to join forces with U.S. Stem Cell, Inc., a leader in regenerative medicine solutions, to help expand our role in this important market.”

The 21st Century Cures Act, signed into effect in December of 2016, builds on the FDA’s ongoing efforts to advance medical product innovation and ensure that patients get access to treatments as quickly as possible, with continued assurance from high quality evidence that they are safe and effective.

“Patient demand for regenerative medicine procedures as a viable alternative to surgery, as well as the transformative capacity of stem cell therapies, are leading the way to increased acceptance by both the medical and regulatory communities,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc.

Few know that as recently as December 2015 these shares were near $2.00 as stem cell was a sector in biotech that had big multiples and a larger hope for the future. U.S. Stem Cell, Inc. (OTCMKTS:USRM) has renewed this hope for many shareholders who have stayed with the stock. Through consolidation and internal organizational changes the company has combined operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic) which include the development of proprietary cell therapy products. They also generate physician and patient based regenerative medicine and cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.

The White Papers take the time to explain how the science works, and all this company needed was one yes answer from a larger investor to secure financing to jump start operations and ultimately the stock price. USRM is one of the most exciting stories on the OTC – stay tuned we will update the story soon. For more news on $USRM and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.

 

Sign Up for our 100% FREE Oracle Dispatch Newsletter